Itus Stock Buy | Or Sell

The ticker formerly represented ITUS Corporation, which underwent a name change and rebranding to Anixa Biosciences (ANIX) in 2018. Analysts currently view ANIX as a high-potential but high-risk biotech play, with a consensus rating of Strong Buy from multiple firms as of April 2026. Anixa Biosciences (ANIX) Financial Snapshot Buy/Sell Analysis

: Some technical analysis platforms like StockInvest.us have recently downgraded the stock to a Hold candidate due to short-term technical weaknesses and high volatility. Key Considerations ANIX Stock Quote Price and Forecast | CNN

: The average 12-month price target is approximately $10.00 , representing a potential upside of over 220% from its current price near $3.05.

: Major firms like Zacks Investment Research and MarketBeat report a consensus "Strong Buy" or "Buy" rating.